Clinical Trial Update: Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 safety and effectiveness trial of docetaxel plus gefitinib (ZD1839) followed by prostate removal for prostate cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Gefitinib (Gefitinib)

Snippet

Sponsor: Benaroya Research Institute | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED